AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Bavarian Nordic

Transaction in Own Shares Jan 12, 2026

3354_rns_2026-01-12_c6617ae8-1e93-4e2b-ac80-f6d0895773ae.html

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since initiation of the program, the following transactions have been made by Nordea on behalf of Bavarian Nordic:

Number of shares Average purchase price, DKK Transaction value, DKK
January 7, 2026 21,000 197.45 4,146,416
January 8, 2026 54,895 199.11 10,930,385
January 9, 2026 5,000 199.10 995,524
Accumulated under the program 80,895 198.68 16,072,325

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 1,047,740 treasury shares, corresponding to 1.32% of the Company’s share capital.

About Bavarian Nordic

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly

Contact investors:

Europe: Disa Tuominen, IR Manager, [email protected]

US: Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600

Contact media:

Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03

Company Announcement no. 02 / 2026

Attachments

Talk to a Data Expert

Have a question? We'll get back to you promptly.